PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
Sara Raponi(Sapienza University of Rome), Robin Foà(Sapienza University of Rome), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Maria Teresa Gentile(Azienda Ospedaliera di Cosenza), Francesca Romana Mauro(Sapienza University of Rome), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Vincenzo Cappelli(Cornell University), Ilaria Del Giudice(Sapienza University of Rome), Marzia Cavalli(Sapienza University of Rome), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alfonso Piciocchi(Fondazione Gimema Onlus), Luciana Cafforio(Center for Genomic Science), Irene Della Starza(Associazione Italiana Ematologia Oncologia Pediatrica), Lucia Anna De Novi(Sapienza University of Rome), Paola Mariglia(Sapienza University of Rome), Anna Guarini(Sapienza University of Rome), Katia Bontempi(Fondazione Gimema Onlus), Caterina Ilari(Sapienza University of Rome), Giovanna Cutrona(Ospedale Policlinico San Martino)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378